Loading...
Keywords
Last Name
Institution
 Back to Details

Connection

Craig Friesen to Eosinophilia

This is a "connection" page, showing publications Craig Friesen has written about Eosinophilia.

 
Connection Strength
  
 
 
4.702
  
  1. Singh V, Singh M, Friesen CA. Colonic mucosal eosinophilia in children without inflammatory bowel disease. Hum Pathol. 2021 07; 113:34-38.
    View in: PubMed
    Score: 0.759
  2. Singh M, Singh V, Friesen CA. Colonic mucosal inflammatory cells in children and adolescents with lactase deficiency. Pathol Res Pract. 2020 Jun; 216(6):152971.
    View in: PubMed
    Score: 0.707
  3. Turner D, Friesen C. Authors' response. J Pediatr Gastroenterol Nutr. 2013 Oct; 57(4):e25-6.
    View in: PubMed
    Score: 0.450
  4. Turner D, Wolters VM, Russell RK, Shakhnovich V, Muise AM, Ledder O, Ngan B, Friesen C. Anti-TNF, infliximab, and adalimumab can be effective in eosinophilic bowel disease. J Pediatr Gastroenterol Nutr. 2013 May; 56(5):492-7.
    View in: PubMed
    Score: 0.437
  5. Neilan NA, Dowling PJ, Taylor DL, Ryan P, Schurman JV, Friesen CA. Useful biomarkers in pediatric eosinophilic duodenitis and their existence: a case-control, single-blind, observational pilot study. J Pediatr Gastroenterol Nutr. 2010 Apr; 50(4):377-84.
    View in: PubMed
    Score: 0.353
  6. Schurman JV, Wu YP, Grayson P, Friesen CA. A pilot study to assess the efficacy of biofeedback-assisted relaxation training as an adjunct treatment for pediatric functional dyspepsia associated with duodenal eosinophilia. J Pediatr Psychol. 2010 Sep; 35(8):837-47.
    View in: PubMed
    Score: 0.350
  7. Friesen CA, Neilan NA, Schurman JV, Taylor DL, Kearns GL, Abdel-Rahman SM. Montelukast in the treatment of duodenal eosinophilia in children with dyspepsia: effect on eosinophil density and activation in relation to pharmacokinetics. BMC Gastroenterol. 2009 May 11; 9:32.
    View in: PubMed
    Score: 0.332
  8. Friesen CA, Sandridge L, Andre L, Roberts CC, Abdel-Rahman SM. Mucosal eosinophilia and response to H1/H2 antagonist and cromolyn therapy in pediatric dyspepsia. Clin Pediatr (Phila). 2006 Mar; 45(2):143-7.
    View in: PubMed
    Score: 0.266
  9. Keever-Keigher MR, Harvey L, Williams V, Vyhlidal CA, Ahmed AA, Johnston JJ, Louiselle DA, Grundberg E, Pastinen T, Friesen CA, Chevalier R, Smail C, Shakhnovich V. Genomic insights into pediatric intestinal inflammatory and eosinophilic disorders using single-cell RNA-sequencing. Front Immunol. 2024; 15:1420208.
    View in: PubMed
    Score: 0.239
  10. Friesen CS, Shakhnovich V, Toren P, Retke B, Schurman J, Colombo J, Deacy A, Friesen CA, Abdel-Rahman S. A Pilot Study of Ketotifen in Patients Aged 8-17 Years with Functional Dyspepsia Associated with Mucosal Eosinophilia. Paediatr Drugs. 2024 Jul; 26(4):451-457.
    View in: PubMed
    Score: 0.235
  11. Friesen CA, Kearns GL, Andre L, Neustrom M, Roberts CC, Abdel-Rahman SM. Clinical efficacy and pharmacokinetics of montelukast in dyspeptic children with duodenal eosinophilia. J Pediatr Gastroenterol Nutr. 2004 Mar; 38(3):343-51.
    View in: PubMed
    Score: 0.231
  12. Neustrom MR, Friesen C. Treatment of eosinophilic gastroenteritis with montelukast. J Allergy Clin Immunol. 1999 Aug; 104(2 Pt 1):506.
    View in: PubMed
    Score: 0.168
  13. Yang M, Geng L, Chen P, Wang F, Xu Z, Liang C, Li H, Fang T, Friesen CA, Gong S, Li D. Effectiveness of dietary allergen exclusion therapy on eosinophilic colitis in Chinese infants and young children = 3 years of age. Nutrients. 2015 Mar 11; 7(3):1817-27.
    View in: PubMed
    Score: 0.124
  14. Issa A, Edwards J, Singh M, Friesen C, Edwards S. Presence of Increased Mast Cells in Infants and Children with Volume and Variety Limited Intake. Nutrients. 2022 Jan 15; 14(2).
    View in: PubMed
    Score: 0.050
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.